康寧傑瑞(09966.HK)確認無僱員蓄意非法披露臨床最新進展
康寧傑瑞製藥-B(09966.HK)公布,留意到若干媒體相關報道,聲稱有關臨床最新進展的內幕消息已於內幕消息公告披露前發布,導致價格不尋常波動。
公司已迅速採取措施應對價格不尋常波動及媒體報道,其中包括及時與監管部門溝通,進行內部調查,尤其是相關臨床數據管理流程的保密性及合規性,及委聘獨立調查機構調查參與KN046-303的外部相關方。
經作出合理查詢及內部調查後,公司確認並無任何權限獲取KN046-303的揭盲數據,公司並不知悉有任何證據證明集團僱員蓄意或罔顧後果地於刊發內幕消息公告前非法披露有關KN046-303的臨床最新進展,及11月1日至14日期間,並無董事、高級管理人員或關鍵僱員買賣股份。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.